MedTrace Logo

Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma

NCT00210379 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2009-07-22

No results posted yet for this study

Summary

The primary objective assess the clinical activity of combination doxorubicin-containing chemotherapy plus monoclonal antibody anti-CD20 (Rituximab) plus intrathecal prophylactic chemotherapy and loco-regional radiotherapy in primary localised testicular DLCL and to assess the toxicity of this therapeutic strategy

Conditions

  • Lymphoma, B Cell

Interventions

DRUG

rituximab

DRUG

CHOP

DRUG

intrathecal methotrexate

PROCEDURE

radiotherapy

Sponsors & Collaborators

  • International Extranodal Lymphoma Study Group (IELSG)

    lead OTHER

Principal Investigators

  • Andreas Sarris, MD · International Extranodal Lymphoma Study Group

  • Emanuele Zucca, MD · International Extranodal Lymphoma Study Group/Oncology Institute of Southern Switzerland (IOSI)

  • Mary Gospodarowicz, MD · Radiation Oncology. Princess Margareth Hospital. Toronto

  • Umberto Vitolo, MD · Hematology Division. Ospedale San Giovanni Battista. Torino

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-11-30
Primary Completion
2004-11-30
Completion
2007-03-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00210379 on ClinicalTrials.gov